Skip to main content

Table 2 Comparison of the tumour and liver uptake of radioimmunoconjugates (RICs) estimated by region of interest (ROI) analysis of PET images and biodistribution (BOD) studies

From: Dose predictions for [177Lu]Lu-DOTA-panitumumab F(ab′)2 in NRG mice with HNSCC patient-derived tumour xenografts based on [64Cu]Cu-DOTA-panitumumab F(ab′)2 – implications for a PET theranostic strategy

Percent injected dose/g (mean ± SEM)
  Tumour Liver
Time p.i. PET a BOD b P-value c PET a BOD b P-value c
6 h 8.8 ± 2.3 9.3 ± 1.0 n.s. 11.2 ± 0.5 8.4 ± 0.8 n.s.
24 h 10.3 ± 1.3 14.9 ± 1.1 n.s. 9.5 ± 0.2 7.5 ± 1.0 n.s.
48 h 10.9 ± 1.1 9.8 ± 1.3 n.s. 7.2 ± 0.3 6.2 ± 0.1 0.04
  1. aUptake of [64Cu]Cu-DOTA-panitumumab Fab´)2 estimated by ROI analysis of PET images expressed in percent injected dose/g (%ID/g; mean ± SEM, n = 4)
  2. bUptake of [64Cu]Cu-DOTA-panitumumab F(ab´)2 estimated by BOD analysis expressed in %ID/g (mean ± SEM, n = 4)
  3. cComparison of ROI and BOD analysis by a Mann-Whitney U test (P < 0.05)